Saved in:
Bibliographic Details
Main Authors: Jeetendra Kumar Prajapati, Aman Shukla
Format: Recurso digital
Language:English
Published: Zenodo 2025
Subjects:
Online Access:https://doi.org/10.5281/zenodo.14614194
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866902294023372800
author Jeetendra Kumar Prajapati
Aman Shukla
author_facet Jeetendra Kumar Prajapati
Aman Shukla
contents <p><span>A major public health problem nowadays is the evolution of antimicrobial medication resistance on a global scale. Decades of study have not eliminated the devastating impact of bacterial illnesses on human health. These include TB, septicaemia, staphylococcal skin infections, pneumonia, and others. Microbes resistant to many regularly used antibiotics have emerged as a result of the overuse and misuse of antibiotics in recent decades, which might make future infections very challenging to cure. Due to the widespread medication resistance and, in particular, the appearance of their multidrug-resistant phenotypes, the management of these illnesses continues to be a significant issue in modern times. This highlights the critical need for new classes of antimicrobials that can effectively combat multidrug-resistant bacteria. Our findings provide light on the eternal possibilities of bacteria in this area, which is quite encouraging. The latest research confirms that uncommon actinomycetes might be a great source of new antimicrobial agents that effectively inhibit the development of many multidrug-resistant bacteria. Our research leads us to believe that uncommon actinomycetes and the bioactive metabolites they produce might be a viable alternative to conventional antibiotics in the fight against multidrug-resistant bacteria. Research into the use of microbial natural products in the pharmaceutical industry has a promising future.</span></p>
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_14614194
institution Zenodo
language eng
publishDate 2025
publisher Zenodo
record_format zenodo
spellingShingle Investigating novel compounds to combat Multidrug-Resistant bacterial infections
Jeetendra Kumar Prajapati
Aman Shukla
Antimicrobial susceptibility, bioactive extracts, multi-drug resistance, rare actinomycetes, S. pneumoniae, time-kill kinetics
<p><span>A major public health problem nowadays is the evolution of antimicrobial medication resistance on a global scale. Decades of study have not eliminated the devastating impact of bacterial illnesses on human health. These include TB, septicaemia, staphylococcal skin infections, pneumonia, and others. Microbes resistant to many regularly used antibiotics have emerged as a result of the overuse and misuse of antibiotics in recent decades, which might make future infections very challenging to cure. Due to the widespread medication resistance and, in particular, the appearance of their multidrug-resistant phenotypes, the management of these illnesses continues to be a significant issue in modern times. This highlights the critical need for new classes of antimicrobials that can effectively combat multidrug-resistant bacteria. Our findings provide light on the eternal possibilities of bacteria in this area, which is quite encouraging. The latest research confirms that uncommon actinomycetes might be a great source of new antimicrobial agents that effectively inhibit the development of many multidrug-resistant bacteria. Our research leads us to believe that uncommon actinomycetes and the bioactive metabolites they produce might be a viable alternative to conventional antibiotics in the fight against multidrug-resistant bacteria. Research into the use of microbial natural products in the pharmaceutical industry has a promising future.</span></p>
title Investigating novel compounds to combat Multidrug-Resistant bacterial infections
topic Antimicrobial susceptibility, bioactive extracts, multi-drug resistance, rare actinomycetes, S. pneumoniae, time-kill kinetics
url https://doi.org/10.5281/zenodo.14614194